VESICARE LS
PeakNDAORALSUSPENSIONPriority Review
Approved
May 2020
Lifecycle
Peak
Competitive Pressure
8/100
Data completeness
3/8 — Basic
Priority Review
Drug data last refreshed 15h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
VESICARE LS is an oral suspension formulation of solifenacin, an anticholinergic agent approved by the FDA in May 2020. The drug treats overactive bladder (OAB) by relaxing bladder smooth muscle to reduce urinary urgency, frequency, and incontinence. This liquid formulation enhances dosing flexibility and patient compliance, particularly for populations requiring dose titration or having difficulty swallowing tablets.
$0.032BPart D
Peak4.6 years to LOEProduct is at peak commercial maturity with modest Part D utilization; marketing team likely focused on maintaining market share against established OAB competitors rather than driving growth.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Why This Matters for Your Career
LOE in ~5 years — strategic planning for patent cliff underway
Worked on VESICARE LS at Astellas? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.